VENN Venn Life Sciences Holdings Plc

TIDMORPH

Open Orphan PLC

03 September 2019

03 September 2019

Open Orphan Plc

("Open Orphan" or the "Company")

Investor Event Attendance and Presentation

Open Orphan presents at Shares Investor Evening, London

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at the Shares Investor Evening tomorrow from 18:00 at Novotel Hotel Tower Bridge, London, EC3N 2NR.

Cathal Friel, Open Orphan's Chief Executive Officer will be presenting from 18:30 onwards to update existing and potential investors on the Company's business plans for 2019-2020.

The event will provide an opportunity for investors to hear about the progress being made by the Company following the reverse takeover of Venn Life Sciences and the potential for Open Orphan moving forward.

A link to the presentation will be made available on the Company website following the event.

For further information on the Shares Investor Evening, please visit the event website https://www.sharesmagazine.co.uk/events/event/shares-investor-evening-london-040919

Enquiries:

Open Orphan Plc Tel: +353 1 5499 341

Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900

John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363

Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980

Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAUGUUABUPBGQP

(END) Dow Jones Newswires

September 03, 2019 02:01 ET (06:01 GMT)

Venn Life Sciences (LSE:VENN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024

Venn Life Sciences (LSE:VENN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024